However, Pfizer announced its intention to develop a modified version of the drug “Danoglipron”.
This drug belongs to a new class of successful treatments based on a component such as the gastrointestinal hormone glucagon or GLP-1 (GLP-1).GLP-1This leads to a feeling of fullness and weight loss.
“Danoglibron” differs from competing drugs already on the market in that it is not given by injection, but is given orally in the form of tablets.
During the clinical trial, Pfizer tested taking these pills twice a day, but said it wanted to focus on a new once-a-day formulation.
The clinical trial included a few hundred obese participants without type 2 diabetes.
Pfizer explained that the side effects in this trial were similar to those that can occur with this type of drug, but “it is noteworthy that their rates were high” because “cases of nausea reached 73 percent, vomiting reached 47 percent, and diarrhea reached 25 percent.”
More than half of the participants who received this drug discontinued treatment.
However, “Danoglipro” has been shown to lead to weight loss between 8 percent and 13 percent over 32 weeks or between 5 percent and 9.5 percent over 26 weeks.
A report quoted Pfizer senior executive Michael Tolston as confirming that “an improved once-daily formulation of tanoglipron could play an important role in the treatment of obesity.”
The highly lucrative anti-obesity drug market is currently dominated by the Danish “Novo Nordisk” group with its drug “Vecovi” and the American “Eli Lilly” company “Zebound”. America last month.